{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:41Z","timestamp":1790352581732,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute Limb Ischemia (ALI) carries a high morbidity and mortality rate that is compounded in the cancer patient. Though it is a relatively uncommon event, it is of extremely high adverse impact and carries poor awareness among clinicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective review of electronic medical records was performed of cancer patients presenting with acute limb ischemia (ALI) to the tertiary cancer center\u2019s urgent care center or as inpatient between January 1, 2014 and January 1, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of the 29 cancer patients with ALI, 12 (41%) died within 3\u2009month and 9 (31%) patients died within 1\u2009months of ALI diagnosis. 65% had long term adverse outcome after ALI \u2013 31% with death in 1\u2009month, 2 (7%) with an amputation, 5 (17%) with lifestyle-limiting claudication, and 3 (10%) with subsequent wound ulceration or gangrene. Patients not eligible for standard of care (12 patients, 41%) (RR 2.33 95% CI [1.27\u20134.27],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.01) and heparin administration \u22656\u2009h from presentation (19 patients, 65%) (RR 2.81 [1.07\u20137.38],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) were at increased risk of adverse outcome. Atypical\/confounded presentation of ALI (13 patients, 45%) (RR 1.84 95% CI [1.03\u20133.29],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), pulse exam not documented (12 patients, 41.4%) (RR 1.95 [95% CI [1.14\u20133.32],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), and patients with services other than a vascular specialist initially consulted (8 patients, 27.6%) (RR 1.91 95% CI [1.27\u20132.87],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009\u00a00.01) were significant risk factors for heparin administered \u22656\u2009h from presentation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ALI is devastating in cancer patients, with a high number presenting with atypical\/confounded signs and symptoms which delays treatment. Heparin administered \u22656\u2009h from presentation is associated with adverse outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08659-x","type":"journal-article","created":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:03:03Z","timestamp":1628812983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acute limb ischemia in a cancer patient has high morbidity, high mortality, and atypical presentation: a tertiary cancer center\u2019s retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yolanda","family":"Bryce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Amoateng","family":"Emmanuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Agrusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etay","family":"Ziv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Harnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Huq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto Santos","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"issue":"4","key":"8659_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3400\/avd.ra.18-00074","volume":"11","author":"H Obara","year":"2018","unstructured":"Obara H, Matsubara K, Kitagawa Y. Acute Limb Ischemia. Ann Vasc Dis. 2018;11(4):443\u20138. https:\/\/doi.org\/10.3400\/avd.ra.18-00074.","journal-title":"Ann Vasc Dis"},{"issue":"23","key":"8659_CR2","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1056\/NEJMcp1006054","volume":"366","author":"M Creager","year":"2012","unstructured":"Creager M, Kaufman J, Conte M. Acute Limb Ischemia. N Engl J Med. 2012;366(23):2198\u2013206. https:\/\/doi.org\/10.1056\/NEJMcp1006054.","journal-title":"N Engl J Med"},{"issue":"7","key":"8659_CR3","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.avsg.2011.06.002","volume":"25","author":"JS Tsang","year":"2011","unstructured":"Tsang JS, Naughton PA, O\u2019Donnell J, Wang TT, Moneley DS, Kelly CJ, et al. Acute limb ischemia in cancer patients: should we surgically intervene? Ann Vasc Surg. 2011;25(7):954\u201360. https:\/\/doi.org\/10.1016\/j.avsg.2011.06.002.","journal-title":"Ann Vasc Surg"},{"issue":"19","key":"8659_CR4","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.115.016424","volume":"132","author":"DP Howard","year":"2015","unstructured":"Howard DP, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM. Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation. 2015;132(19):1805\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016424.","journal-title":"Circulation"},{"issue":"11","key":"8659_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/CIR.0000000000000470","volume":"69","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):1465\u2013508. https:\/\/doi.org\/10.1161\/CIR.0000000000000470.","journal-title":"J Am Coll Cardiol"},{"key":"8659_CR6","first-page":"E137","volume":"14","author":"P Chopra","year":"2017","unstructured":"Chopra P, Igyarto Z, Martinsen BJ. A multi-regional physician survey of peripheral artery disease: implications for improved awareness and expedited referral. Vasc Dis Manag. 2017;14:E137\u201342.","journal-title":"Vasc Dis Manag"},{"issue":"6 Suppl","key":"8659_CR7","first-page":"278","volume":"78","author":"RN Baird","year":"1996","unstructured":"Baird RN. The vascular patient as a litigant. Ann R Coll Surg Engl. 1996;78(6 Suppl):278\u201382.","journal-title":"Ann R Coll Surg Engl"},{"issue":"4","key":"8659_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ejvs.2008.06.018","volume":"36","author":"GA Markides","year":"2008","unstructured":"Markides GA, Subar D, Al-Khaffaf H. Litigation claims in vascular surgery in the United Kingdom\u2019s NHS. Eur J Vasc Endovasc Surg. 2008;36(4):452\u20137. https:\/\/doi.org\/10.1016\/j.ejvs.2008.06.018.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"8659_CR9","volume-title":"Failure to diagnose acute limb ischaemia (ALI); an avoidable cause of limb loss","author":"A Shearman","year":"2012","unstructured":"Shearman A, Shearman C. Failure to diagnose acute limb ischaemia (ALI); an avoidable cause of limb loss: Association of Surgeons of Great Britain and Ireland, International Surgical Congress; 2012. In: www.asgbi.org.uk\/liverpool2012\/pdfs\/oral_shortpapers\/Vascular_I.pdf. abstract 0812"},{"key":"8659_CR10","volume-title":"Early detection and treatment of acute limb ischaemia","author":"National Patient Safety Agency","year":"2011","unstructured":"National Patient Safety Agency. Early detection and treatment of acute limb ischaemia. 2011. In: www.nrls.npsa.nhs.uk\/resources\/?EntryId45=130172."},{"issue":"S2","key":"8659_CR11","first-page":"2","volume":"3","author":"BT Katzen","year":"2019","unstructured":"Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia. Rev Cardiovasc Med. 2019;3(S2):2\u20136 PMID: 12556737.","journal-title":"Rev Cardiovasc Med"},{"key":"8659_CR12","doi-asserted-by":"publisher","first-page":"f2681","DOI":"10.1136\/bmj.f2681","volume":"346","author":"S Brearley","year":"2013","unstructured":"Brearley S. Acute leg ischaemia. BMJ. 2013;346:f2681. https:\/\/doi.org\/10.1136\/bmj.f2681.","journal-title":"BMJ"},{"key":"8659_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0002-9610(96)00129-8","volume":"172","author":"AJ Comerota","year":"1996","unstructured":"Comerota AJ, Weaver FA, Hosking JD, et al. Results of a prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg. 1996;172:105\u201312. https:\/\/doi.org\/10.1016\/S0002-9610(96)00129-8.","journal-title":"Am J Surg"},{"key":"8659_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/s1051-0443(96)70734-0","volume":"7","author":"DC Diffin","year":"1996","unstructured":"Diffin DC, Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower limb ischemia: a review of limb-salvage and mortality statistics. J Vasc Interv Radiol. 1996;7:57\u201363. https:\/\/doi.org\/10.1016\/s1051-0443(96)70734-0.","journal-title":"J Vasc Interv Radiol"},{"issue":"16","key":"8659_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1056\/NEJM199804163381603","volume":"338","author":"K Ouriel","year":"1998","unstructured":"Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or peripheral arterial surgery (TOPAS) investigators. N Engl J Med. 1998;338(16):1105\u201311. https:\/\/doi.org\/10.1056\/NEJM199804163381603.","journal-title":"N Engl J Med"},{"issue":"1","key":"8659_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/1708538114537048","volume":"23","author":"D Silverberg","year":"2015","unstructured":"Silverberg D, Yalon T, Reinitz ER, Yakubovitch D, Segev T, Halak M. Acute limb ischemia in cancer patients: aggressive treatment is justified. Vascular. 2015;23(1):55\u201361. https:\/\/doi.org\/10.1177\/1708538114537048.","journal-title":"Vascular"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08659-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08659-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08659-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:03:13Z","timestamp":1628812993000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08659-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8659"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08659-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-438538\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from our institution the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB) with need for consent waived in accordance to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Individual consent for publication was not obtained as individual details, images, or videos were not utilized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Etay Ziv, MD, PhD has the following grants - AACR, SIR, RSNA, NANETS, Druckenmiller, MSK Society, MSK FGI, MSK Radiology Seed, Ethicon, Novartis, none of which are of competing interest for this study. The remainder of the authors do not have any potential competing interest to disclose. Dr. Yolanda Bryce, MD has consulted for Hologic.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"916"}}